Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to equity ratio high or low?
The debt to equity ratio of 0.01 is 94% below its 5-year average of 0.24, near the high end of its 5-year range (-24.54–0.86).
As of the fiscal period ended Tuesday, June 30, 2026. 100.28% above its 12-month average of -4.75.
Reported quarterly debt to equity ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 0.01.
DEBT TO EQUITY RATIO
0.01
DEBT TO EQUITY RATIO AVG TTM
-4.75
DEBT TO EQUITY RATIO AVG 3Y
0.26
DEBT TO EQUITY RATIO AVG 5Y
0.24
DEBT TO EQUITY RATIO AVG 10Y
N/A
DEBT TO EQUITY RATIO AVG 15Y
N/A
DEBT TO EQUITY RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
+100.28%
CURRENT VS 3Y AVG
-94.95%
CURRENT VS 5Y AVG
-94.48%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.16
median of 351 covered companies
CURRENT VS SECTOR MEDIAN
-91.74%
vs the sector median at left
Anteris Technologies Global Corp.
Market Cap
$734.10M
Debt to Equity Ratio
0.01
TTM Avg
-4.75
3Y Avg
0.26
5Y Avg
0.24
Market Cap
$719.64M
Debt to Equity Ratio
N/A
TTM Avg
0.58
3Y Avg
1.04
5Y Avg
0.73
Market Cap
$749.55M
Debt to Equity Ratio
0.39
TTM Avg
0.12
3Y Avg
0.63
5Y Avg
0.50
Market Cap
$709.33M
Debt to Equity Ratio
2.75
TTM Avg
3.44
3Y Avg
3.49
5Y Avg
2.78
Market Cap
$767.46M
Debt to Equity Ratio
0.00
TTM Avg
0.01
3Y Avg
0.03
5Y Avg
0.31
Market Cap
$698.60M
Debt to Equity Ratio
0.00
TTM Avg
0.09
3Y Avg
0.09
5Y Avg
0.07
Market Cap
$774.32M
Debt to Equity Ratio
0.04
TTM Avg
0.01
3Y Avg
0.01
5Y Avg
0.01
Market Cap
$775.72M
Debt to Equity Ratio
0.01
TTM Avg
0.01
3Y Avg
0.01
5Y Avg
0.01
Market Cap
$776.24M
Debt to Equity Ratio
0.56
TTM Avg
0.77
3Y Avg
0.65
5Y Avg
0.53
| NAME | MARKET CAP | DEBT TO EQUITY RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Anteris Technologies Global Corp. (AVR) | $734.10M | 0.01 | -4.75 | 0.26 | 0.24 |
| Achieve Life Sciences, Inc. (ACHV)vs › | $719.64M | N/A | 0.58 | 1.04 | 0.73 |
| Candel Therapeutics, Inc. (CADL)vs › | $749.55M | 0.39 | 0.12 | 0.63 | 0.50 |
| Collegium Pharmaceutical, Inc. (COLL)vs › | $709.33M | 2.75 | 3.44 | 3.49 | 2.78 |
| Avalo Therapeutics, Inc. (AVTX)vs › | $767.46M | 0.00 | 0.01 | 0.03 | 0.31 |
| Faeth Therapeutics, Inc. (FTH)vs › | $698.60M | 0.00 | 0.09 | 0.09 | 0.07 |
| Attovia Therapeutics, Inc. (ATTO)vs › | $774.32M | 0.04 | 0.01 | 0.01 | 0.01 |
| Design Therapeutics, Inc. (DSGN)vs › | $775.72M | 0.01 | 0.01 | 0.01 | 0.01 |
| Geron Corporation (GERN)vs › | $776.24M | 0.56 | 0.77 | 0.65 | 0.53 |
| Annexon, Inc. (ANNX)vs › | $688.14M | 0.13 | 0.11 | 0.12 | 0.11 |
Debt/Equity
0.01
Current Ratio
14.20
Debt to Equity measures financial leverage by comparing total debt to shareholders' equity.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO EQUITY RATIO |
|---|---|
| 2026-06-30 | 0.01 |
| 2026-03-31 | 0.01 |
| 2025-12-31 | -24.54 |
| 2025-09-30 | 0.64 |
| 2025-06-30 | 0.12 |
| 2025-03-31 | 0.05 |
| 2024-12-31 | 0.02 |
| 2024-09-30 | 0.86 |
| 2024-06-30 | 0.66 |
| 2024-03-31 | 0.55 |
| 2023-12-31 | 0.08 |
| 2023-09-30 | 0.00 |
| 2023-06-30 | 0.14 |
| 2023-03-31 | 0.14 |
| 2022-12-31 | 0.11 |
| 2022-09-30 | 0.11 |
| 2022-06-30 | 0.13 |
| 2022-03-31 | 0.13 |
| 2021-12-31 | 0.40 |
| 2021-09-30 | 0.40 |
